Balanced news tone
News Sentiment
GMAB sentiment intelligence
Genmab A/S news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +14.2% over four weeks, trend inactive, and near fair-value range.
Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Genmab stock trades mixed as investors weigh Darzalex growth and upcoming earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Jul 2026 13:30
- Source
- ad-hoc-news.de
Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 11:22
- Source
- Stock Titan
Genmab stock reflects biotech growth focus for long-term investors
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Jul 2026 05:13
- Source
- ad-hoc-news.de
Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings
- Tone
- Positive 95/100
- Event
- Market update
- Published
- 13 Jul 2026 09:19
- Source
- DirectorsTalk Interviews
Genmab stock reflects the biotech group's global oncology ambitions
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 07:02
- Source
- ad-hoc-news.de
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 08 Jul 2026 07:00
- Source
- Market source
Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- Stock Titan
Genmab lymphoma trial cuts progression risk 60% in phase 3 study
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Stock Titan
Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Market source
Genmab (NASDAQ: GMAB) issues 185 new shares from employee warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Stock Titan
Orbis reduces Genmab (GMAB) stake to 4.99% of voting rights
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Truist Assigns Buy Rating to Genmab (GMAB)
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 05 Jun 2026 07:00
- Source
- Market source
Genmab A/ S stock (DK0010272202): board share sale keeps focus on Denmark
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 May 2026 07:00
- Source
- ad-hoc-news.de
Genmab’s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 07:00
- Source
- Stock Titan
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- Market source
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Market source
Genmab A/S (GMAB) stock falls on Q1 2026 Earnings
- Tone
- Negative 22/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Quiver Quantitative
Genmab (GMAB) Rated Outperform on Oncology Pipeline
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 02 May 2026 07:00
- Source
- Market source
A Look At Genmab’s (CPSE:GMAB) Valuation After Recent Share Price Volatility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Apr 2026 07:00
- Source
- Market source
Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- Market source
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Mar 2026 08:00
- Source
- ChartMill
How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 03 Mar 2026 08:00
- Source
- Market source
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 20 Feb 2026 08:00
- Source
- Market source
Genmab (GMAB)’s Future Potential Underappreciated by Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jan 2026 08:00
- Source
- Market source
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2025 08:00
- Source
- Business Wire
REG-Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Apr 2025 07:00
- Source
- TradingView